
Medical Policy



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.

***Current Policy Effective Date: 11/1/23**
(See policy history boxes for previous effective dates)

Title: Radiofrequency Ablation of Peripheral Nerves to Treat Pain including Coolief Cooled RF

Description/Background

NERVE RADIOFREQUENCY ABLATION

Nerve radiofrequency ablation (RFA) is a minimally invasive method that involves the use of heat and coagulation necrosis to destroy tissue. A needle electrode is inserted through the skin and then into the tissue to be ablated. A high-frequency electrical current is applied to the target tissue. A small sphere of tissue is coagulated around the needle by the heat generated. It is theorized that the thermal lesioning of the nerve destroys peripheral sensory nerve endings, resulting in the alleviation of pain. Cooled radiofrequency (RF) treatment is a variation of nerve RFA using a special device that applies more energy at the desired location without excessive heat diffusing beyond the area, causing less tissue injury away from the nerve. The goal of ablating the nerve is the same.

For the indications assessed in this evidence review, nerve RFA should be distinguished from RF energy applied to areas other than the nerve to cause tissue damage. Some patients have been treated for plantar fasciitis with a fasciotomy procedure using a RF device. This procedure does not ablate a specific nerve.

Cryoneurolysis

Cryoneurolysis is being investigated to alleviate pain. Temperatures of -20° to -100°C applied to a nerve cause Wallerian (anterograde axonal) degeneration, with disruption of nerve structure and conduction but maintenance of the perineural and epineural elements of the nerve bundle. Wallerian degeneration allows complete regeneration and recovery of nerve function in about 3 to 5 months. The iovera[®] cryoablation system is a portable handheld device that applies percutaneous and targeted delivery of cold to superficial peripheral nerves.

Coolief is a cooled RF device currently being used for RFA of peripheral nerves of the back, hip and knee. Cooled RF devices generate heat using radio waves and are often used for RF denervation (RFD) in nerve tissue. The radio waves are delivered to the targeted nerves via

needles inserted through the skin. Sterile water pumped through the device circulates and cools the RF probe, allowing treatment of an area larger than conventional RFD. The tip of the needle heats the surrounding tissue.

Table 1. Types of Radiofrequency Ablation

Type	Procedure	Tissue Temperature	Key Differences
Standard RFA	Electrode tip provides thermal energy for 90 – 130 seconds	70 – 90° C	Longer term pain relief but with more adjacent thermal tissue injury and limitation in size and shape of lesion.
Pulsed RFA	Non-ablative - provides 20 ms pulses every 30 seconds	42° C	Limits tissue damage but results in shorter duration of pain relief.
Cooled RFA	Water circulates through RF electrode to cool the tip	60° C	Larger lesion with limited thermal injury to tissue. Longer term pain relief.

RF: radiofrequency; RFA: radiofrequency ablation
Adapted from Oladeji et al (2019)²

PLANTAR FASCIITIS

Plantar fasciitis is a common cause of foot pain in adults, characterized by deep pain in the plantar aspect of the heel, particularly on arising from bed. While the pain may subside with activity, in some individuals the pain persists and can impede activities of daily living. On physical examination, firm pressure will elicit a tender spot over the medial tubercle of the calcaneus. The exact etiology of plantar fasciitis is unclear, although repetitive injury is suspected. Heel spurs are a common associated finding, although it has never been proven that heel spurs cause the pain. Asymptomatic heel spurs can be found in up to 10% of the population.

Treatment

Most cases of plantar fasciitis are treated with conservative therapy, including rest or minimization of running and jumping, heel cups, and nonsteroidal anti-inflammatory drugs. Local steroid injection may also be used. Improvement may take up to 1 year in some cases.

OSTEOARTHRITIS (Knee and Hip)

Knee and hip osteoarthritis is common, costly, and often the cause of substantial disability. Prevalence increases with age, from about 24% among those 60 to 64 years of age to as high as 40% in those 70 to 74 years of age.³³ Knee osteoarthritis is characterized by pain upon initiation of movement or walking. As osteoarthritis progresses, the pain becomes continuous and joint functionality is severely impaired. Hip joint pain is characterized by groin pain with radiation to the buttocks or upper-outer thigh.

Treatment

Treatment for osteoarthritis aims to alleviate pain and improve function. However, most treatments do not modify the natural history or progression of osteoarthritis and are not considered curative. Nonsurgical modalities used include exercise; weight loss; various supportive devices; acetaminophen or nonsteroidal anti-inflammatory drugs, such as ibuprofen; nutritional supplements (glucosamine, chondroitin); and intra-articular viscosupplements. Corticosteroid injection may be considered when relief from nonsteroidal anti-inflammatory drugs is insufficient, or the patient is at risk of gastrointestinal adverse effects. If symptom relief

is inadequate with conservative measures, invasive treatments may be considered. Operative treatments for symptomatic osteoarthritis of the knee include arthroscopic lavage and cartilage débridement, osteotomy, and, ultimately, total joint arthroplasty. Surgical procedures intended to repair or restore articular cartilage in the knee (e.g., abrasion arthroplasty, microfracture techniques, autologous chondrocyte implantation) are appropriate only for younger patients with focal cartilage defects secondary to injury and are not addressed in this evidence review.

Occipital Neuralgia

Occipital neuralgia is a specific type of headache that is located on one side of the upper neck, back of the head, and behind the ears, and sometimes extending to the scalp, forehead, and behind the eyes. The pain, which may be piercing, throbbing, or electric-shock-like, follows the course of the greater and lesser occipital nerves. Occipital neuralgia is believed to occur due to pressure or irritation to the occipital nerves, which may result from injury, entrapment by tight muscles, or inflammation.

Treatment

Treatment may include massage and rest, muscle relaxants, nerve blocks, and injection of steroids directly into the affected area.

Cervicogenic Headache

Cervicogenic headache is a headache that is secondary to a disorder of the cervical spine. The pain may be referred from facet joints, intervertebral discs, or soft tissue. The pain is constant rather than throbbing and may be aggravated by movements of the neck or pressure to certain areas on the neck. The first 3 cervical spinal nerves can refer pain to the head. The C1 suboccipital nerve innervates the atlanto-occipital joint; the C2 spinal nerve and the C3 dorsal ramus have close proximity to and innervate the C2-C3 facet joint. The C2-3 facet joint is the most frequent source of a cervicogenic headache. A diagnosis of a cervicogenic headache may be confirmed by an anesthetic block of the lateral atlanto-axial joint, the C2-3 facet joint, or the C3-4 facet joint.

Treatment

Treatment may include nerve blocks, physical therapy, and exercise.

Regulatory Status

A number of RF generators and probes have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Some examples are listed in Table 2.

In 2017, the COOLIEF Cooled Radiofrequency Probe (Avanos, previously known as Halyard Health) was cleared for marketing by the FDA through the 510(k) process to be used in conjunction with a radiofrequency generator to create lesions in nervous tissue (K163461). One of the indications is specifically for "creating radiofrequency lesions of the genicular nerves for the management of moderate to severe knee pain of more than 6 months with conservative therapy, including medication, in patients with radiologically-confirmed osteoarthritis (grade 2-4) and a positive response (>50%reduction in pain) to a diagnostic genicular nerve block."

Table 2. Radiofrequency and Cryoneurolysis Devices

Device	Manufacturer	Clearance	Date	FDA Product Code
SInergy®/Bayless Pain Management Probe	Kimberly-Clark/Baylis	K053082	2005	GXD
NeuroTherm® NT 2000	NeuroTherm	K111576	2011	GXD
iovera	Pacira (formerly Myoscience)	K133453	2014	GXH
COOLIEF® Cooled Radiofrequency Kit	Avanos, (formerly Halyard Health)	K163236	2016	GXI
COOLIEF® Cooled RF Probe	Avanos, (formerly known as Halyard Health)	K163461	2017	GXI
Rulo(TM) Radiofrequency Lesion Probe	Epimed International	K190256	2019	GXI
Coolief Cooled Radiofrequency Kit Advanced	Avanos, (formerly known as Halyard Health)	K203066	2020	GXI
Coolief Radiofrequency Generator (CRG) System	Avanos, (formerly known as Halyard Health)	K192491	2020	GXI

Medical Policy Statement

Radiofrequency ablation of peripheral nerves to treat pain (e.g., plantar fasciitis, occipital neuralgia, cervicogenic headache, osteoarthritis, etc.) including Coolief Cooled RF is experimental/investigational. It has not been scientifically demonstrated to improve patient clinical outcomes.

Inclusionary and Exclusionary Guidelines

N/A

CPT/HCPCS Level II Codes *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure.)*

Established codes:

N/A

Other codes (investigational, not medically necessary, etc.):

64640*

64625*

****This code is not covered when used for the procedures discussed within this policy.***

Note: Code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at Blue Cross or BCN to verify coverage.

Rationale

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

RADIOFREQUENCY ABLATION [including cooled RF] For OSTEOARTHRITIS (Knee, Hip)

Clinical Context and Therapy Purpose

The purpose of RFA in individuals with knee OA who have severe refractory pain is to provide a treatment option that is an alternative to intra-articular injections or total joint replacement. Pain in OA can be transmitted via the genicular sensory nerves, which are branches of the femoral, tibial, peroneal, saphenous, and obturator nerves around the knee.² The genicular nerve branches can be divided into a four-quadrant system—superomedial, superolateral, inferomedial, and inferolateral. Nerves in the superomedial, superolateral, and inferomedial quadrants are located near the periosteum, but the inferolateral branch is close to the peroneal nerve and is usually avoided. The exact neuroanatomy around the knee is variable and can also be affected by chronic OA. Although the location of the target nerves is aided by palpating the bony landmarks and fluoroscopy, variability may prevent the exact localization. Diagnostic nerve blocks have been evaluated to confirm the location of the genicular nerves and predict efficacy. In addition to the genicular nerves, studies have reported RFA of the saphenous nerve, the sciatic nerve, the femoral, tibial, saphenous nerves, and peripatellar plexus in combination, and the intra-articular joint space.³

The question addressed in this evidence review is: Does the use of RFA improve the net health outcome in individuals with knee osteoarthritis?

The following **PICO** was used to select literature to inform this review.

Populations

The relevant population of interest is individuals with knee osteoarthritis.

Interventions

The therapy being considered is RFA of the superomedial, inferomedial, and superolateral genicular nerves. Due to the variable location of the genicular nerves, it is thought that the increased area of denervation associated with cooled-RFA may be more effective than standard or pulsed RFA.

Comparators

The following therapy is currently being used to make decisions treating osteoarthritis: conservative management, which may include analgesics, physical therapy, or intra-articular injections.

Outcomes

The most clinically relevant outcome measures for pain treatments are measures of pain severity and functional limitations. Pain is a subjective, patient-reported measure. Therefore, pain outcomes require quantifiable pre- and posttreatment measures. Pain is most commonly measured with a visual analog scale (VAS) or 11-point numeric rating scale (NRS).

The Oxford Knee Score is scaled between 12 and 60, with 12 representing the best outcome. Quantifiable pre- and post-treatment measures of functional status are also used, such as the 12-Item and 36-Item Short-Form Health Survey.

The Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) is also frequently used to evaluate function due to osteoarthritis. The WOMAC includes 3 subscales: pain, stiffness, and physical functioning. Scores range from 0 to 96, with higher scores indicating greater disability.

The Lysholm Knee Score (LKS) has 8 domains to assess limitations in function, including limp, use of supports, locking, instability, pain, swelling, stair-climbing, and squatting. Scores range from 0 to 100, with lower scores indicating greater disability.

Because of the variable natural history of osteoarthritis and the subjective nature of the outcome measures, RCTs are needed to determine whether outcomes are improved with interventions for pain. Trials should include a homogenous population of individuals with a defined clinical condition, use standardized outcome measures when possible, and define a priori the clinically significant magnitude of response.

The effect of RFA is likely to be transient, so the period for follow-up is within a month to determine procedural success and at least one year to evaluate durability. Longer follow-up is needed to evaluate whether denervation of sensory nerves of the knee could have adverse long-term effects on knee anatomy in individuals with OA.

Study Selection Criteria

We selected methodologically credible studies, using these principles:

- To assess efficacy outcomes, we sought comparative controlled prospective trials, with a preference for RCTs with a minimum of six months outcomes, and systematic reviews of RCTs

- To assess long-term outcomes and adverse effects, we sought single-arm studies with longer periods of follow-up and/or larger populations.
- Within each category of study design, we included studies with larger sample sizes and longer duration.

Systematic Reviews

Characteristics of systematic reviews are described in Tables 3 and 4.

Chen et al (2021) conducted a systematic review of RFA for the treatment of knee OA.⁴ The authors (including several affiliated with the American Academy of Orthopedic Surgeons) identified 7 RCTs published through 2019 that met inclusion criteria. Quality of the studies was assessed based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology for risk of bias of randomization, allocation concealment, blinding, incomplete data, selective reporting, and other bias. Five of the trials were rated as high quality^{5,6,7,8,9}, despite lack of blinding in most and moderate risk of bias for allocation concealment and other biases. Two ^{10,11} were rated as moderate quality. A majority of the studies were conducted outside of the U.S., with a number of participants ranging from 24 to 151. Techniques included RFA and cooled RFA. RFA was compared to non-treated controls or sham procedures, intra-articular corticosteroids, or hyaluronic acid. There was high heterogeneity due to the variability in comparators and outcome measures that limited meta-analysis, but analysis of the mean differences for the individual studies showed general agreement that RFA had a benefit on pain, function, and composite scores compared to the control treatments at 3 and 6 month follow-up.

The trials by Davis et al (2018), El-Hakeim et al (2018) and Xiao et al (2018) with 6 month follow-up, along with later RCTs that are not included in the systematic review, are described in greater detail below.

Table 3. Systematic Review Characteristics

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Chen et al (2021) ⁴	1966 - 2019	7	Individuals with OA of the knee who were treated with RFA or C-RFA		RCT	up to 12 months

OA: osteoarthritis; RFA: radiofrequency ablation; C-RFA: cooled radiofrequency ablation; RCT: randomized controlled trial.

Table 4. Comparison of RCTs Included in the Systematic Review by Chen et al (2021)

Study	Trial Size	Prognostic Block	RF Method	Comparator	Follow-up	Limitations
Choi et al (2011) ⁵	38	Yes	RFA	Sham	3 months	Short follow-up
Shen et al (2017) ¹⁰	54		RFA	Standard Treatments	3 months	Short follow-up
Sari et al (2018) ⁶	73	No	RFA	IA Steroid	3 months	Short follow-up
Davis et al (2018) ⁸	151	Yes	C-RFA	IA Steroid	6 months	Study participants not blinded

El-Hakeim et al (2018) ⁹	60	No	RFA	Acetaminophen and NSAIDs	6 months	Study participants not blinded
Ray et al (2018) ⁷	24	Yes	RFA	IA Hyaluronic Acid	3 months	Short follow-up
Xiao et al (2018) ¹¹	96	No	RFA	IA Hyaluronic Acid	6 months	Patients not blinded

C-RFA: cooled radiofrequency ablation; IA: intra-articular; NSAIDs: nonsteroidal anti-inflammatory drug; RCT: randomized controlled trial; RFA: radiofrequency ablation.

Table adapted from Jamison and Cohen (2018) ³

Randomized Controlled Trials

Characteristics and results of randomized controlled trials are described in Tables 5 and 6. El-Hakeim et al (2018) reported a single-center RCT that compared RFA of the genicular nerves to conventional analgesics in 60 patients with Kellgren-Lawrence stage III or IV knee OA.⁹ The investigators did not use a positive response to nerve blocks to determine who to treat but did assess the accuracy of the target by sensory and motor responses to stimulation. The best approach to identify the genicular nerves is uncertain.¹² VAS pain scores decreased from baseline in both groups and were significantly lower in the RFA group from 2 weeks to 6 months after treatment. WOMAC scores, which were assessed by a clinician who was blinded to treatment, were significantly better only at the 6 months time point.

Davis et al (2018) reported on a multicenter randomized trial comparing cooled RFA to corticosteroid injection in 151 patients who had chronic (>6 months) knee pain unresponsive to conservative therapy.⁸ At 1 month after treatment, both groups showed a reduction in pain, with a 0.9-point difference on an 11-point NRS. By 3 months after treatment, pain scores had increased in the steroid group, while pain scores in the RFA group remained low throughout the 6 month follow-up. At the 6-month follow-up, 74.1% of patients in the RFA group were considered responders ($\geq 50\%$ decrease in the NRS), compared with 16.2% of patients treated with steroid injections ($p < .001$). Twelve month follow-up was reported in 2018.¹³ Out of the 76 patients randomized to RFA, 52 (68%) patients were available for follow-up at 12 months. Out of those 52, 34 (65%) reported at least a 50% decrease in pain on an NRS. Limitations of this observational portion of the study include the 32% loss to follow-up and the lack of blinding for this subjective measure. All but 4 of the patients in the intra-articular steroid arm had crossed over to cooled RFA by the 12-month follow-up.

Twelve to 24 month follow-up of a subset of patients treated with RFA in the RCT by Davis et al (2018) was reported by Hunter et al (2020) and is shown in Table 7.^{8,14} There were 42 patients randomized to RFA and 41 randomized to the control group who crossed over to RFA at 6 months who qualified for follow-up at participating sites. Of the 83 potential participants, 15 had additional procedures (e.g. steroid injection, total knee arthroplasty, hyaluronic injection, repeat RFA) and were not included in the analysis, 35 (42.2%) could not be reached or declined to participate, and 33 (40%) consented for the study. Although 44% of patients who participated in follow-up maintained their improvement in pain scores, this was a small percentage of the patients who received treatment. Interpretation is limited due to the small number of patients and the potential for bias in this non-blinded study.

Another manufacturer-sponsored trial on cooled RFA for knee osteoarthritis was reported by Chen et al (2020).¹⁵ The investigators randomized 177 patients to RFA or a single injection of

hyaluronic acid (Synvisc ONE). Although widely used, the efficacy of hyaluronic acid has not been supported by evidence.¹⁶ Therefore, it might be considered a placebo treatment. Crossovers to RFA (n=68, 82.9%) were allowed at 6 months. A major limitation of this publication is that results were reported only for the 83% of control patients who crossed over; the authors noted that the remainder of the patients reported long-term pain relief from hyaluronic acid.

An independent study by Elawamy et al (2021) compared pulsed radiofrequency to a single injection of platelet-rich plasma in 200 patients with OA (NCT03886142).¹⁷ VAS scores showed an improvement of 50% (from a score of 6 to 3) in both groups at 3 months, with values returning to a score of 5 by the sixth month. Scores on the Index of Severity for OA of the Knee were reduced from 7 at baseline to 4 at the third month, increasing to 5 at the sixth month. Twelve month scores were not reported. Platelet-rich plasma is not considered a standard of care treatment for OA and there were a number of additional limitations in conduct and reporting of this study. Limitations of these studies, which include potential for bias due to lack of patient blinding and insufficient number of patients in follow-up, are described in Tables 8 and 9.

Overall, the available studies have methodological limitations and the number of patients studied for this common condition is low.

Table 5. Summary of Key RCT Characteristics

Study	Countries	Sites	Participants	Interventions	
				Active	Comparator
Davis et al (2018) ⁸	U.S.	11	151 patients with chronic (>6 mo) knee pain unresponsive to conservative therapy ^a ; pain score ≥ 6 ; OA grades 2-4; Oxford Knee Score of ≤ 35 ; a positive diagnostic genicular nerve block ^{a,b}	Cooled RFA of the genicular nerves under fluoroscopic guidance (n=76)	Intra-articular steroid (n=75)
El-Hakeim et al (2018) ⁹	Egypt	1	60 patient with stage III or IV knee OA	RFA of the genicular nerves under fluoroscopic guidance (n=30)	Conventional analgesics (n=30)
Xiao et al (2018) ¹¹	China	1	96 patients with OA with VAS >6 and LKS <60 who had abandoned other therapeutic measures	RFA of the genicular nerves guided by a plexus nerve stimulator (n=49)	Single intra-articular hyaluronic acid injection (n=47)
Chen et al (2020) ¹⁵	U.S.	Multicenter	177 patients with knee OA	Cooled RFA of the genicular nerves under fluoroscopic guidance (n=89)	Single hyaluronic acid injection (Synvisc-One, n=88)

Elawamy et al (2021) ¹⁷	Egypt	2	200 patients with knee OA grade III or IV refractory to conservative management	Pulsed RFA with identification of the genicular nerves based on proximity to the arteries by ultrasound and sensory stimulation (n=100)	Single intra-articular platelet rich plasma (n=100)
------------------------------------	-------	---	---	---	---

LKS: Lysoim Knee Score; OA: osteoarthritis; RCT: randomized controlled trial; RFA: radiofrequency ablation; VAS: visual analog score.

^a Conservative treatment included physical therapy, oral analgesics: ≤60 mg morphine equivalence, stable for 2 months; intra-articular injections with steroids and/ or viscosupplementation), body mass index (BMI) <40, and reporting ≥50% response to blocks as

^bAt least 50% reduction in numeric rating scale for pain with anesthetic injection to the superomedial and inferomedial branches of the saphenous nerve and the superolateral branch of the femoral nerve.

Table 6. Summary of Key RCT Results

Study	Mean Pain Scores (SD)			Responders at 6 Months, % ^a	Function	
	1 Month	3 Months	6 Months		Mean Oxford Knee Score at 6 Months (SD)	Global Perceived Effect at 6 Months, %
Davis et al (2018) ⁸	NRS					
N	136	132	126	126	125	126
RFA	3.0 (2.3)	2.8 (2.2)	2.5 (2.3)	74.1	35.7 (8.8)	91.4
Steroid injection	3.9 (2.2)	5.2 (2.0)	5.9 (2.2)	16.2	22.4 (8.5)	23.9
p-Value	.025	<.001	<.001	<.001	<.001	<.001
El-Hakeim et al (2018) ⁹	VAS			WOMAC		
	2 Weeks	3 Months	6 Months	2 weeks	3 Months	6 Months
N	60	60	60	60	60	
RFA	2.47 (0.3)	2.83 (0.5)	3.13 (0.3)	93.53 (1.9)	21.67 (4.4)	24.23 (4.3)
Analgesics	3.63 (0.27)	4.93 (0.2)	5.73 (0.26)	54.07 (3.0)	30.93 (2.5)	37.1 (1.9)
p-Value	.004	<.001	<.001	.17	.10	<.001
Xiao et al (2018) ¹¹	VAS			Lysoim Knee Score		
	3 Days	6 Months	12 Months	3 Days	6 Months	12 Months
N	96	96	96	96	96	96
RFA	3.38 (1.02)	2.41 (1.06)	3.12 (1.03)	78.1 (7.5)	68.3 (6.6)	84.6 (4.3)
Hyaluronic Acid	5.11 (1.13)	5.13 (1.12)	7.01 (1.01)	61.1 (5.3)	54.1 (6.2)	43.2 (6.1)
p-Value	<.05	<.05	<.05	<.05	<.05	<.05

Chen et al (2020) ¹⁵	NRS				WOMAC	
	1 Month	6 Months	12 Months	Responders at 6 Months, %^a	6 Months	12 Months
N	153	144	128	144	144	128
RFA (95% CI)	3.0 (2.5 to 3.5)	2.7 (2.2 to 3.2)	2.8 (2.2 to 3.4)	71.1%	33.6 (28.4 to 38.9)	33.2 (27.5 to 38.9)
Hyaluronic Acid	NR	NR	NR	NR	NR	NR
Subgroup of control patients who crossed over to RFA at 6 mo	4.2 (3.6 to 4.8)	5.0 (4.4 to 5.6)	3.0 (2.4 to 3.6)	29.4%	58.1 (53.4 to 62.8)	38.4 (32.7 to 44.1)
p-Value	.002	<.001	.618	<.001	<.001	.1996
Elawamy et al (2021) ¹⁷	VAS				ISK	
	1 Week	6 Months	12 Months	1 Week	6 Months	12 Months
N	200	NR	NR	200	NR	NR
RFA	3	5	5	5	4	NR
Platelet-rich Plasma	3	5	6	6	6	NR
p-Value	NR	NR	NR	NR	NR	

ISK: Index of Severity for Osteoarthritis of the Knee; NR: not reported; NRS: numeric rating scale; RCT: randomized controlled trial; RFA: radiofrequency ablation; SD: standard deviation; VAS: visual analog score; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.

^a Greater than 50% reduction in the NRS.

Table 7. Extended Follow-up of Patients Treated with RFA

Study	Mean Pain Scores (SD)				Function	
	At 12 Months	At 18 Months	At 24 Months	Responders at 18 Months, % ^a		
Davis et al (2018), Hunter et al (2020) ^{8,14}	NRS					
N (randomized and crossover)	30	25	18	25	25	18
RFA	3.0 (2.5)	3.1 (2.7)	3.6 (2.8)	44.0	47.2 (8.1)	46.8 (10.3)

NRS: numeric rating scale; RFA: radiofrequency ablation; SD: standard deviation;

^a Greater than 50% reduction in the NRS.

Table 8. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Davis et al (2018) ⁸					1. Follow-up >6 mo is needed to evaluate durability of the procedure. Extended follow-up is in progress (see Table 18).

El-Hakeim et al (2018) ⁹	4. Study population was not selected by a positive response to a nerve block		2. Controls received only analgesics and physical therapy if needed		1. Follow-up >6 mo is needed to evaluate durability of the procedure
Xiao et al (2018) ¹¹	4. Study population was not selected by a positive response to a nerve block		2. Efficacy of a single injection of hyaluronic acid as an active comparator is not supported by evidence		
Chen et al (2020) ¹⁵			2.. Efficacy of a single injection of hyaluronic acid as an active comparator is not supported by evidence		
Elawamy et al (2021) ¹⁷	4. Study population was not selected by a positive response to a nerve block	1. Both groups received analgesics and physical therapy, but these were not recorded.	2. Efficacy of a single injection of platelet-rich plasma as an active comparator is not supported by evidence		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 9. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Davis et al (2018) ⁸		1. Study population was not blinded to treatment assignment, which might have affected subjective scores		1. Unequal loss to follow-up 3. Crossovers to RFA were allowed at 6 mo		2. The study used Wilcoxon signed-rank sum test rather than a repeated-measures test

El-Hakeim et al (2018) ^{9a}	2. Allocation concealment not described	1. Study population was not blinded to treatment assignment, which might have affected subjective scores				2. The study did not use a repeated-measures test for the different time points.
Xiao et al (2018) ^{11c}	2. Allocation concealment not described	1. Study population was not blinded to treatment assignment, which might have affected subjective scores			1. Power calculations were not reported	2. The study did not use a repeated-measures test for the different time points.
Chen et al (2020) ^{15d}		1. Study population was not blinded to treatment assignment, which might have affected subjective scores	2. Results were reported only for controls who failed treatment and crossed over			2. The study did not use a repeated-measures test for the different time points.
Elawamy et al (2021) ^{17e}		1. Study population was not blinded to treatment assignment, which might have affected subjective scores		6. It is unclear how many patients completed the 12 month follow-up		2, 4. The study did not use a repeated-measures test and there was no comparison between groups.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment. RFA: radiofrequency ablation.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4.

Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Observational Studies

Observational studies can provide information on durability that is not available from RCTs (see Tables 10 and 11). Follow-up to 12 months was reported in a prospective study of 25 patients.¹⁸ The response rate was 88% at 1 month after treatment, decreasing to 64% at 6 months and 32% at 12 months.

Kapural et al (2019) reported a retrospective assessment of pain relief in 183 out of 205 (86%) patients who had been treated with RFA of the genicular nerves and returned for evaluation.¹⁹ At follow-up (time not reported), 65% of patients reported greater than 50% pain

relief and 77% had a decrease in VAS of at least 2 points. The average duration of reported pain relief was 12.5 months (range 0 to 35). Opioid use was not reduced, but this result is confounded because 80% of patients reported at least 1 additional source of chronic pain (e.g., back, shoulder). The publication notes that pain scores were assessed at three and six months and at the latest visit, but is unclear about the range of follow-up and the time of the reported results.

These observational studies suggest that between one-third and two-thirds of patients will continue to report at least a 50% reduction in pain at 12 months following RFA of the genicular nerves.

Table 10. Summary of Key Case Series Characteristics

Study	Country	Participants	Treatment Delivery	Follow-Up
Santana Pineda et al (2017) ¹⁸	E.U.	25 patients with grade III-IV knee OA (n=24) or after total knee arthroplasty (n=1) and intractable pain with VAS ≥5 for >6 mo	RFA of superior medial, superior lateral, and inferior medial genicular nerves with electrode tips placed on periosteal areas and guided by ultrasound and neurostimulation	12 mo
Kapural et al (2019) ¹⁹	U.S.	205 patients with knee pain (21 had pain after TKA) who had a positive response to a geniculate block and underwent C-RFA. Mean VAS pain prior to treatment was 8.5 and 2.2 after the nerve block	C-RFA of the geniculate nerves under fluoroscopic guidance as described in Davis et al (2018)	NR

C-RFA: cooled radiofrequency ablation; NR: not reported; OA: osteoarthritis; RFA: radiofrequency ablation; TKA: total knee arthroplasty; VAS: visual analog scale.

Table 11. Summary of Key Case Series Results

Study	Treatment	Proportion With ≥50% Improvement in pain, n/N (%) (95% CI)		
		At 1 Month	At 6 Months	At 12 Months
Santana Pineda et al (2017) ¹⁸	RFA of genicular nerves	22/25 (88%)	16/25 (64%)	8/25 (32%)
Kapural et al (2019) ¹⁹	C-RFA of genicular nerves	NR	NR	65% at a mean of 12.5 months (range, 0 to 35)

CI: confidence interval; C-RFA: cooled radiofrequency ablation ; NR: not reported; RFA: radiofrequency ablation.

Coolief Cooled RF System for Pain due to Degenerative Hip Disease

Coolief is a cooled radiofrequency ablation (CRFA) system. It was cleared by the U.S. Food and Drug Administration (FDA) for use in patients with chronic knee pain, but it has not been cleared for treatment of hip pain due to degenerative hip disease. CRFA for chronic hip pain may have promise, in particular because of the larger lesion size it creates, compared with conventional radiofrequency ablation (RFA). Evidence from 3 clinical studies suggests that the Coolief system reduces hip pain to a statistically and clinically significant degree and is associated with minimal complications (Kapural et al., 2018; Kapural et al., 2021; Tran et al., 2022).³³⁻³⁵ However, the long-term (≥ 6 to 12 months) durability of effect is unclear and only 1

study measured functional outcomes (see Table 12). No systematic reviews or guidelines addressing Coolief by name were identified.

Table 12 Key Outcome Summary

Outcome	Study Findings and Quality
Pain relief	3 very poor-quality pretest-posttest studies reported SS and clinically meaningful pain relief at 6 mos (Kapural et al. 2018 ; Tran et al., 2022) or 12 mos (Kapural et al., 2021) f/u after Coolief tx and compared w/ BL, although repeat CRFA was performed for some patients.
Opioid use	2 very poor-quality pretest-posttest studies reported no SS differences in opioid use at 6 or 12 mos f/u after Coolief tx compared w/ BL (Kapural et al. 2018 ; Kapural et al., 2021). 1 very poor-quality pretest-posttest study reported reductions in opioid use at 6 mos f/u after Coolief tx compared w/ BL; however, the outcome was not statistically analyzed (Tran et al., 2022).
Function	1 very poor-quality pretest-posttest study reported SS and clinically meaningful improvement from BL in mean Hip Disability and Osteoarthritis Score (HOOS) at 6 mos f/u after CRFA w/ Coolief (Tran et al., 2022).
AEs	3 very poor-quality pretest-posttest studies reported no or mild self-limiting AEs (Kapural et al., 2018 ; Kapural et al., 2021 ; Tran et al., 2022).

Key: AE(s), adverse event(s); BL, baseline; f/u, follow-up; SS, statistically significant(ly); tx, treatment

Safety

In 2021, the Spine Intervention Society's Patient Safety Committee published an article on the safety of genicular nerve RFA.²⁰ The committee reviewed case reports of septic arthritis, pes anserine tendon injury, third-degree skin burn, and clinically significant hematoma and/or hemarthrosis with RFA of the genicular nerves, concluding that larger cohort studies are needed to determine the incidence of these complications for this emerging technology.

Section Summary: Osteoarthritis (Knee, Hip)

Knee OA is a common disorder in older adults. RFA of the genicular nerves has the potential to alleviate pain and improve function in this population, and might also delay or eliminate the need for TKA. To date, the evidence on RFA for knee pain includes systematic reviews of RCTs, RCTs with 24 to 200 patients (including 4 with a minimum of 6-month follow-up), and prospective observational studies with 12 to 24 months of follow-up. The systematic review found high heterogeneity due to the variability in type of RFA used, comparators and outcome measures that limited meta-analysis, but analysis of the mean differences for the individual studies showed general agreement that RFA had a benefit on pain, function, and composite scores compared to the control treatments at 3 and 6 month follow-up. Trials have compared RFA to sham procedures, intra-articular steroid injection, intra-articular hyaluronic acid injection, and platelet-rich plasma injection. Although intra-articular steroid injection is an established treatment for OA pain, it has limited durability. The efficacy of hyaluronic acid has been challenged and that of platelet-rich plasma is uncertain so it is unclear whether these would be considered active or placebo controls. Few of the studies were blinded, which may have biased the subjective outcome measures. Additional limitations in design and conduct include suboptimal statistical analyses and reporting of loss to follow-up. The 2 multi-center

trials conducted in the U.S. used anesthetic nerve block under fluoroscopic guidance and compared efficacy of cooled RFA to either steroid injection or hyaluronic acid injection. Both studies reported a responder rate above 70% at 6 months which was significantly greater than the control conditions. Given that OA of the knee is a common condition, study in a larger number of patients, preferably in blinded studies with active and sham controls and follow-up of at least 12 months is needed to determine the benefits and potential harms of this treatment.

Cryoneurolysis for Knee Osteoarthritis or Total Knee Arthroplasty

Clinical Context and Therapy Purpose

The purpose of cryoneurolysis in patients who have OA or TKA is to provide a treatment option that is an alternative to standard therapies. Pain control in patients with knee OA can delay TKA, while pain control following TKA is essential for patients to participate in physical therapy and promote recovery.

The question addressed in this evidence review is: Does the use of cryoneurolysis improve the net health outcome in patients with OA or following TKA?

The following **PICO** was used to select literature to inform this review.

Population

The relevant population of interest are patients with OA or who are undergoing TKA.

Interventions

The therapy being considered is percutaneous cryoneurolysis of the anterior femoral cutaneous nerve and/or the infrapatellar branch of the saphenous nerve.

Comparators

The following therapies are currently being used to make decisions about treating OA or TKA: conservative management, which may include corticosteroid injection or oral medications, for OA, and opioid or peripheral nerve blocks with anesthetics, for TKA.

Outcomes

The most clinically relevant outcome measures for pain treatments are measures of pain severity and functional limitations. Pain is most commonly measured with a VAS or NRS. The Oxford Knee Score is scaled between 12 and 60, with 12 representing the best outcome. Quantifiable pre- and posttreatment measures of functional status are also used, such as the 12-Item and 36-Item Short-Form Health Survey. The WOMAC score is also frequently used to evaluate function due to OA. The time for follow-up is within days to determine procedural success and at least 6 months to a year to evaluate durability.

Randomized Controlled Trials

Radnovich et al (2017) reported a double-blind multicenter RCT of cryoneurolysis for patients with mild-to-moderate OA (see Table 13).²¹ Compared with sham-treated patients, cryoneurolysis resulted in a greater decrease in WOMAC pain score, WOMAC total score, and VAS score at 30 days (see Table 14). The cryoneurolysis group also had better WOMAC total scores at 90 days but not at 60 days. Improvements in VAS scores did not differ significantly between active and sham treatment groups at 60 and 90 days.

Table 13. Summary of Key RCT Characteristics

Study	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Radnovich et al (2017) ²¹	U.S.	17	2013-2016	180 patients with mild-to-moderate (grade II-III) knee OA with knee pain ≥ 40 mm/100-mm VAS and $\geq 50\%$ reduction in pain on diagnostic block	n=121 percutaneous cryoneurolysis targeting the IBSN with anatomic landmarks (visual and palpation)	n=59 sham cryoneurolysis with a sham tip and local anesthetic

IBSN: infrapatellar branch of the saphenous nerve; OA: osteoarthritis; RCT: randomized controlled trial; VAS: visual analog score.

Table 14. Summary of Key RCT Results

Study	Change in WOMAC Score (SEM)				VAS Score (SEM)		
	Pain at 30 Days	Total at 30 Days	At 60 Days	At 90 Days	At 30 Days	At 60 Days	At 90 Days
Radnovich et al (2017) ²¹							
N	180	180	180	180	180	180	180
Cryoneurolysis	-16.65 (1.26)	-78.78 (5.81)	-75.75 (5.87)	-80.31 (5.89)	-40.09 (2.87)	-38.53 (2.91)	-37.90 (3.01)
Sham	-9.54 (1.63)	-48.26 (7.51)	-56.28 (7.58)	-56.51 (7.60)	-27.83 (3.68)	-32.44 (3.73)	-31.58 (3.86)
Diff (95% CI)	-7.12 (-11.01 to -3.22)	-30.52(-48.52 to -12.53)	-19.47(-37.64 to -1.30)	-23.80(-42.02 to -5.57)	-12.25(-21.16 to -3.35)	-6.09(-15.11 to 2.94)	-6.32(-15.66 to 3.01)
p	.004	.001	.036 ^a	.011	.007	.185	.183

CI: confidence interval; Diff: difference; RCT: randomized controlled trial; SEM: standard error of mean; VAS: visual analog score; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.

^a Statistical significance was set at a 1-sided level of 0.025.

Tables 15 and 16 display notable limitations identified in the studies evaluated.

Table 15. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Radnovich et al (2017) ²¹	4. A more relevant population would be patients with moderate- to-severe knee osteoarthritis				

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 16. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Radnovich et al (2017) ²¹						2. Unclear whether data were modeled for each time point independently or longitudinally

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Technical Issues

As noted in a review by Gabriel and Ilfeld (2018), several technical issues have yet to be resolved, including the optimal number of applications for each nerve, the duration of treatment, and the duration of thawing before moving the cannula.²² The most effective method for determining the location of the probe (e.g., ultrasound or using anatomic landmarks) also needs to be established.

Section Summary: Cryoneurolysis for Knee Osteoarthritis

An RCT with 180 patients has compared cryoneurolysis with sham treatment in patients who had knee OA. Cryoneurolysis resulted in a greater decrease in WOMAC pain, WOMAC total, and VAS score at 30 days compared with sham-treated controls. Subsequent measurements showed no significant benefit of cryoneurolysis on WOMAC score at 60 days or in VAS scores at 60 or 90 days. Several technical issues including the optimal number of applications for each nerve, the duration of treatment, and the duration of thawing before moving the cannula, have yet to be resolved.

Radiofrequency Ablation for Plantar Fasciitis

Clinical Context and Therapy Purpose

The purpose of RFA in patients who have plantar fasciitis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of RFA improve the net health outcome in patients with plantar fasciitis?

The following **PICO** was used to select literature to inform this review.

Population

The relevant population of interest is patients with plantar fasciitis.

Interventions

The therapy being considered is RFA.

Comparators

The following therapy is currently being used to make decisions about treating plantar fasciitis: conservative management, which may include corticosteroid injection.

Outcomes

The most clinically relevant outcome measures for pain treatments are measures of pain severity and functional limitations. Pain is a subjective, patient-reported measure. Therefore, pain outcomes require quantifiable pre- and posttreatment measures. Pain is most commonly measured using a VAS. Quantifiable pre- and posttreatment measures of functional status are also used, such as the American Orthopedic Foot and Ankle Society (AOFAS) ankle-hindfoot score. The AOFAS ankle-hindfoot scores range from 0 to 100, with up to 40 points for pain, 50 points for functional aspects, and 10 points for alignment. A high score indicates a better outcome. The time for follow-up is within days to determine procedural success and at least 6 months to a year to evaluate durability.

Study Selection Criteria

Because of the variable natural history of plantar fasciitis and the subjective nature of the outcome measures, RCTs are needed to determine whether outcomes are improved with interventions for pain. Trials should include a homogenous population of patients with a defined clinical condition, use standardized outcome measures when possible, and define a priori the clinically significant magnitude of response.

Randomized Controlled Trials

Two double-blind sham-controlled randomized trials have assessed RFA for the treatment of chronic heel pain (see Table 17). Wu et al (2017) randomized 36 patients to ultrasound-guided pulsed radiofrequency of the posterior tibial nerve.²³ First step pain, average pain, and the AOFAS ankle-hindfoot score were assessed at baseline and at 1, 4, 8, and 12 weeks. Scores at 12 weeks are shown in Table 2. Changes in VAS score in the sham group were modest (<1 on a 10-point VAS) and of short duration (statistically significant at weeks 1 and 4, but not weeks 8 and 12). The AOFAS ankle-hindfoot score was 60.55 at baseline and 60.05 at 12 weeks in the sham group. In the RFA group, VAS scores at weeks 1, 4, 8, and 12 were all significantly lower than baseline ($p < 0.001$), and the AOFAS ankle-hindfoot score increased from 55.5 to 87.6 ($p < 0.001$). The improvements in pain and function were greater in the RFA group than in the control group ($p < 0.001$ for all measures).

Landsman et al (2013) reported on a double-blind randomized crossover trial (N=17) of RFA applied along the medial aspect of the heel.²⁴ Crossover to the alternative treatment was allowed at 4 weeks. Outcomes assessed weekly were a pain VAS score reported at the first step in the morning, average pain level, and peak pain level (see Table 18). In a graphic presentation of results, patient pain levels for all 3 outcomes decreased after RFA but showed minimal change after sham. After patients crossed over from sham to RFA, there was a steep drop in all pain outcomes. The maximum follow-up assessment was at 16 weeks and appeared to show similar pain levels throughout the follow-up period.

Table 17. Summary of Key RCT Characteristics

Study	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Wu et al (2017) ²³	Taiwan	1	2014-2016	36 patients (40 feet) with recalcitrant plantar fasciitis	Ultrasound-guided pulsed RF stimulation of the posterior tibial nerve	Sham with ultrasound-guided lidocaine injection
Landsman et al (2013) ²⁴	U.S.	Multicenter	NR	17 patients failed at least 3 prior types of treatments, pain for >3 mo, and VAS score ≥5	RFA procedure, including stimulation of sensory nerves in an awake patient	Sham with all aspects of the RFA procedure, except delivery of RF energy at the final step

NR: not reported; RCT: randomized controlled trial; RF: radiofrequency; RFA: radiofrequency ablation; VAS: visual analog scale.

Table 18. Summary of Key RCT Results

Study	First Step Pain on VAS Score	Average VAS Pain Score		AOFAS Ankle-Hindfoot Score
	<i>At 12 Weeks</i>	<i>At 12 Weeks</i>		
Wu et al (2017) ²³				
N	36	36		36
RFA (SD)	1.79 (1.62)	1.54 (1.26)		87.60 (9.12)
Sham (SD)	6.13 (1.75)	6.09 (1.70)		60.05 (11.38)
	Change At 4 Weeks	Change Score	Change in Peak Pain	
Landsman et al (2013) ²⁴				
N	17	17	17	
RFA	5.0	4.06	5.33	
Sham	1.33	0.8	1.80	
p	.30	.047	.048	

AOFAS: American Orthopedic Foot and Ankle Society; RCT: randomized controlled trial; RFA: radiofrequency ablation; VAS: 10-cm visual analog score.

Tables 19 and 20 display notable limitations identified in each study.

Table 19. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of Follow-Up ^e
Wu et al (2017) ²³	3. Study did not report a minimum VAS for inclusion criteria				

Landsman et al (2013) ²⁴		1. Targeted nerve not clearly defined		1. Crossover allowed at 4 wk
-------------------------------------	--	---------------------------------------	--	------------------------------

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

VAS: visual analog score.

^a Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

Table 20. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Follow-Up ^d	Power ^e	Statistical ^f
Wu et al (2017) ²³						
Landsman et al (2013) ²⁴				3. Crossovers at 4 wk prevented longer-term assessments	1. Power calculations not reported	3. Confidence intervals not reported

The evidence gaps stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4.

Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Case Series

The largest case series with the longest follow-up is by Cozzarelli et al (2010).²⁵ This study reported on a 12-year follow-up of 82 patients who had undergone RFA for heel pain. Patients had undergone RFA between 1994 and 1995 and had been interviewed at 5, 10, and 12 years postprocedure. Baseline pain levels before the procedure were recalled retrospectively at the follow-up interviews. Of 99 patients potentially eligible to be interviewed, the study evaluated 82 patients. The results were presented without statistical testing. It appears that 73 of 82 patients reported being pain-free at 12 years. On a 0-to-10 pain VAS, the pain-free patients rated their preprocedure pain at a mean of 7.1 and at 0 postprocedure.

Cione et al (2009) reported on a retrospective case series of 75 patients treated with RFA.²⁶ Patients who underwent RFA between 2000 and 2003 were surveyed in 2004 to assess preprocedure and current pain status. In this series, the actual number of treated patients is unknown, and preprocedure pain status was assessed only at the follow-up survey. Median preprocedure pain VAS was 9 (range, 2-10) and the postprocedure pain VAS was 1 (range, 0-8; p<.001).

Section Summary: Plantar Fasciitis

Two randomized, double-blind trials and several case series have shown consistent sensory nerve reductions in pain after RFA for patients with heel pain due to plantar fasciitis. However, several case series had methodologic weaknesses. In two of them, all pain assessments were performed retrospectively, including pretreatment pain assessment. The 2 randomized trials enrolled a few subjects. Due to crossover at 4 weeks in one of the trials, the randomized comparison only evaluated outcomes to 4 weeks. To be more confident in the efficacy of this treatment, studies with larger samples and longer follow-up would be necessary. The safety of the procedure cannot be fully evaluated in the small samples studied so far.

Radiofrequency Ablation or Cryoneurolysis for Occipital Neuralgia and Cervicogenic Headache

The purpose of RFA in patients who have occipital neuralgia or a cervicogenic headache is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of neuroablative treatments improve the net health outcome in patients with occipital neuralgia or a cervicogenic headache?

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is patients with occipital neuralgia or a cervicogenic headache.

Interventions

The therapy being considered is RFA or cryoneurolysis. These treatments involve the percutaneous insertion of a catheter that is directed toward the nerve of interest, and are used to ablate the nerve by thermal lesioning.

Comparators

The following therapy is currently being used to make decisions about treating occipital neuralgia or a cervicogenic headache: conservative management.

Outcomes

The most clinically relevant outcome measures for pain treatments are measures of pain severity and functional limitations. Pain is most commonly measured with a VAS or RNS. Quantifiable pre- and posttreatment measures of functional status are also used, such as the 12-Item and 36-Item Short-Form Health Survey. The time for follow-up is within days to determine the procedural success and months to years to evaluate durability.

Systematic Reviews

Grandhi et al (2018) conducted a systematic review of RFA for the treatment of a cervicogenic headache.²⁷ Ten studies met selection criteria, including 3 RCTs, 3 prospective studies, and 4 retrospective studies. There were no high-quality RCTs. Two of the RCTs evaluated RFA of the facet joints and failed to find a benefit of RFA. The third RCT compared RFA with steroid injection of the greater occipital nerve, finding no difference between the groups in the short term, but a longer duration of pain control in the RFA group.

A systematic review by Ducic et al (2014) did not identify any RCTs assessing RFA for chronic occipital neuralgia.²⁸ Reviewers identified 3 case series (total n=131 patients) on pulsed RF treatment. Success rates in these series ranged from 51% to 100%, with an overall success rate of 55%. Follow-up ranged from 3 to 10 months.

Randomized Controlled Trials

A double-blinded RCT of 52 patients who were treated with cryoneurolysis or injection of corticosteroid and local anesthetic in a tertiary pain clinic was reported by Kvarstein et al (2019).²⁹ The investigators noted a temporary benefit of both treatments for cervicogenic headache, but there was no additional benefit for the more invasive procedure. A possibility of adverse effects of repeated occipital cryoneurolysis were noted to include scar and neuroma formation and a risk of neuropathic pain.

Section Summary: Radiofrequency Ablation for Occipital Neuralgia and Cervicogenic Headache

No RCTs of RFA for chronic occipital neuralgia have been identified. A systematic review identified 3 RCTS of RFA for a cervicogenic headache, none of which were high quality. Pain is a subjective, patient-reported measure that is particularly susceptible to a placebo effect. Trials with sham or active controls are needed to evaluate the efficacy of this treatment. One RCT that compared cryoneurolysis with injection of corticosteroid and local anesthetic found no significant improvement with the more invasive treatment.

SUMMARY OF EVIDENCE

For individuals who have knee or hip osteoarthritis who receive radiofrequency ablation of the peripheral nerves, the evidence includes systematic reviews of RCTs, RCTs with 24 to 200 patients (including 4 with a minimum of 6-month follow-up), and prospective observational studies with 12 to 24 months of follow-up. Relevant outcomes include symptoms, functional outcomes, and QOL. Knee OA is a common disorder in older adults. RFA of the genicular nerves has the potential to alleviate pain and improve function in this population, and might also delay or eliminate the need for TKA. At this time, there is high heterogeneity in methods and comparators. The 2 multi-center trials conducted in the U.S. used anesthetic nerve block under fluoroscopic guidance and compared efficacy of cooled RFA to either steroid injection or hyaluronic acid injection. Both studies reported a responder rate approximately 70% at 6 months, which was significantly greater than the control conditions. Given that OA of the knee is a common condition; study in a larger number of patients, preferably blinded with active and sham controls and follow-up of at least 12 months, is needed to determine the benefits and potential harms of this treatment. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have knee OA or TKA who receive cryoneurolysis of peripheral nerves, the evidence includes an RCT with 180 patients and a retrospective comparative study. Relevant outcomes include symptoms, functional outcomes, and QOL. Cryoneurolysis in patients with knee OA resulted in a greater decrease in WOMAC pain score, WOMAC total score, and VAS score at 30 days compared with sham-treated controls. However, subsequent measurements showed no significant benefit of cryoneurolysis on WOMAC score at 60 days or VAS scores at 60 or 90 days. Perioperative cryoneurolysis was shown in a retrospective comparison to reduce the length of stay and opioid use in patients undergoing TKA. These results need to be confirmed in an RCT. Several technical issues including the optimal number of applications for each nerve, the duration of treatment, and the duration of thawing before moving the cannula

have not been resolved. The most effective method for determining probe insertion location (e.g., ultrasound-guided or based on anatomic landmarks) also need to be established. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have plantar fasciitis who receive radiofrequency ablation of the peripheral nerves, the evidence includes two RCTs. Relevant outcomes include symptoms, functional outcomes, and QOL. One of the randomized trials only evaluated 17 patients, and assessment of randomized outcomes was limited to 4 weeks post-treatment. A second RCT evaluated 36 patients out to 12 weeks. The case series generally had small sample sizes, and many had methodologic deficiencies such as retrospective assessment of pain. To be more confident in the efficacy of this treatment, controlled trials with larger samples and longer follow-up would be necessary. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have occipital neuralgia or cervicogenic headache who receive RFA or cryoneurolysis of peripheral nerves, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, and QOL. No RCTs of RFA for chronic occipital neuralgia have been identified. Three RCTs of RFA for a cervicogenic headache have been published, none of which were high quality. Pain is a subjective, patient-reported measure that is particularly susceptible to a placebo effect. Randomized trials with sham or active-controls are needed to evaluate the efficacy of this treatment. One controlled trial found a temporary benefit of cryoneurolysis for cervicogenic headache, but the effect was not significantly better than injection of corticosteroid and local anesthetic. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

Some currently unpublished trials that might influence this review are listed in Table 21.

Table 21. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT02915120	Ultrasound-Guided Pulsed Radiofrequency Of The Genicular Nerves In The Treatment Of Patients With Osteoarthritis Knee Pain: Randomized, Double-Blind, Placebo-Controlled Trial	142	Jul 2022
NCT03774121	Cryoneurolysis for the Management of Chronic Pain in Patients With Knee Osteoarthritis; A Randomized Controlled Study	90	Mar 2023
NCT04145011 ^a	A Prospective, Multi-center, Randomized, Single Blind Clinical Trial Comparing COOLIEF* Cooled Radiofrequency to Conventional Radiofrequency Ablation of the Genicular Nerves in the Management of Knee Pain in an Osteoarthritic Patient Population	153	Aug 2022
Unpublished			
NCT02294864	A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis	50	Apr 2017 (unknown)

NCT02260869	Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain	78	Jun 2019 (terminated due to finances)
NCT02925442 ^a	Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial	150	Feb 2020

NCT: national clinical trial

^a Denotes manufacturer sponsored or cosponsored trial

SUPPLEMENTAL INFORMATION

PRACTICE GUIDELINES AND POSITION STATEMENTS

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Orthopedic Surgeons

The American Academy of Orthopedic Surgeons published a clinical practice guideline on the treatment of osteoarthritis of the knee in 2013.¹⁶ There was no assessment of the more recently developed radiofrequency ablation or cryoneurolysis of genicular nerves.

American College of Rheumatology and Arthritis Foundation

2019 Guidelines from the American College of Rheumatology and the Arthritis Foundation gave a conditional recommendation for radiofrequency ablation for the treatment of knee osteoarthritis.³⁰ The recommendation was based on evidence of a potential analgesic benefit, but the studies used heterogeneous techniques and there was a lack of long-term safety data.

American College of Foot and Ankle Surgeons (ACFAS)

The American College of Foot and Ankle Surgeons (2018) issued consensus guidelines on the diagnosis and treatment of acquired infracalcaneal heel pain.³¹ The safety and efficacy of bipolar radiofrequency were listed as uncertain (neither appropriate nor inappropriate).

U.S. Preventive Services Task Force Recommendations

Not applicable.

Government Regulations

National

No NCD available for this service.

Local

No LCD available for this service.

(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated

Related Policies

1. Cryoablation of Peripheral Nerves (e.g., iovera^o System)Radiofrequency Ablation of Misc Solid Tumors
 2. Radiofrequency Ablation of Primary or Metastatic Liver Tumors
 3. Spinal Surgery: Percutaneous Intradiscal Electrothermal (IDET) Annuloplasty, Radiofrequency Annuloplasty, and Biacuplasty
 4. Spinal Surgery: Percutaneous Disc Decompression Using Laser Energy or Radiofrequency Coblotion
-

References

1. Chua NH, Vissers KC, Sluijter ME. Pulsed radiofrequency treatment in interventional pain management: mechanisms and potential indications-a review. *Acta Neurochir (Wien)*. Apr 2011; 153(4): 763-71. PMID 21116663
2. Oladeji LO, Cook JL. Cooled Radio Frequency Ablation for the Treatment of Osteoarthritis-Related Knee Pain: Evidence, Indications, and Outcomes. *J Knee Surg*. Jan 2019; 32(1): 65-71. PMID 30396206
3. Jamison DE, Cohen SP. Radiofrequency techniques to treat chronic knee pain: a comprehensive review of anatomy, effectiveness, treatment parameters, and patient selection. *J Pain Res*. 2018; 11: 1879-1888. PMID30271194
4. Chen AF, Mullen K, Casambre F, et al. Thermal Nerve Radiofrequency Ablation for the Nonsurgical Treatment of Knee Osteoarthritis: A Systematic Literature Review. *J Am Acad Orthop Surg*. May 01 2021; 29(9): 387-396. PMID 32701684
5. Choi WJ, Hwang SJ, Song JG, et al. Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. *Pain*. Mar 2011; 152(3): 481-487. PMID 21055873
6. Sari S, Aydin ON, Turan Y, et al. Which one is more effective for the clinical treatment of chronic pain in knee osteoarthritis: radiofrequency neurotomy of the genicular nerves or intra-articular injection?. *Int J Rheum Dis*. Oct 2018; 21(10): 1772-1778. PMID 27515095
7. Ray D, Goswami S, Dasgupta SR, Ray S, Basu S. Intra-articular hyaluronic acid injection versus RF ablation of genicular nerve for knee osteoarthritis pain: A randomized open-label, clinical study. *Indian J Pain*. 2018; 32:36-9.
8. Davis T, Loudermilk E, DePalma M, et al. Prospective, Multicenter, Randomized, Crossover Clinical Trial Comparing the Safety and Effectiveness of Cooled Radiofrequency Ablation With Corticosteroid Injection in the Management of Knee Pain From Osteoarthritis. *Reg Anesth Pain Med*. Jan 2018; 43(1): 84-91. PMID 29095245
9. El-Hakeim EH, Elawamy A, Kamel EZ, et al. Fluoroscopic Guided Radiofrequency of Genicular Nerves for Pain Alleviation in Chronic Knee Osteoarthritis: A Single-Blind Randomized Controlled Trial. *Pain Physician*. Mar 2018; 21(2): 169-177. PMID 29565947

10. Shen WS, Xu XQ, Zhai NN, et al. Radiofrequency Thermocoagulation in Relieving Refractory Pain of Knee Osteoarthritis. *Am J Ther.* Nov/Dec 2017; 24(6): e693-e700. PMID 26938761
11. Xiao L, Shu F, Xu C, et al. Highly selective peripheral nerve radio frequency ablation for the treatment of severe knee osteoarthritis. *Exp Ther Med.* Nov 2018; 16(5): 3973-3977. PMID 30344675
12. McCormick ZL, Reddy R, Korn M, et al. A Prospective Randomized Trial of Prognostic Genicular Nerve Blocks to Determine the Predictive Value for the Outcome of Cooled Radiofrequency Ablation for Chronic Knee Pain Due to Osteoarthritis. *Pain Med.* Aug 01 2018; 19(8): 1628-1638. PMID 29300971
13. Davis T, Loudermilk E, DePalma M, et al. Twelve-month analgesia and rescue, by cooled radiofrequency ablation treatment of osteoarthritic knee pain: results from a prospective, multicenter, randomized, cross-over trial. *Reg Anesth Pain Med.* Feb 16 2019. PMID 30772821
14. Hunter C, Davis T, Loudermilk E, et al. Cooled Radiofrequency Ablation Treatment of the Genicular Nerves in the Treatment of Osteoarthritic Knee Pain: 18- and 24-Month Results. *Pain Pract.* Mar 2020; 20(3): 238-246. PMID 31605667
15. Chen AF, Khalouf F, Zora K, et al. Cooled radiofrequency ablation provides extended clinical utility in the management of knee osteoarthritis: 12-month results from a prospective, multi-center, randomized, cross-over trial comparing cooled radiofrequency ablation to a single hyaluronic acid injection. *BMC Musculoskelet Disord.* Jun 09 2020; 21(1): 363. PMID 32517739
16. American Academy of Orthopaedic Surgeons. Treatment of osteoarthritis of the knee, Second edition. Evidence-Based Clinical Practice Guideline. May, 2013
<https://www.aaos.org/globalassets/quality-and-practice-resources/osteoarthritis-of-the-knee/osteoarthritis-of-the-knee-2nd-edition-clinical-practice-guideline.pdf>. Accessed July 28, 2021.
17. Elawamy A, Kamel EZ, Mahran SA, et al. Efficacy of Genicular Nerve Radiofrequency Ablation Versus Intra- Articular Platelet Rich Plasma in Chronic Knee Osteoarthritis: A Single-Blind Randomized Clinical Trial. *Pain Physician.* Mar 2021; 24(2): 127-134. PMID 33740345
18. Santana Pineda MM, Vanlinthout LE, Moreno Martin A, et al. Analgesic Effect and Functional Improvement Caused by Radiofrequency Treatment of Genicular Nerves in Patients With Advanced Osteoarthritis of the Knee Until 1 Year Following Treatment. *Reg Anesth Pain Med.* Jan/Feb 2017; 42(1): 62-68. PMID 27875368
19. Kapural L, Lee N, Neal K, et al. Long-Term Retrospective Assessment of Clinical Efficacy of Radiofrequency Ablation of the Knee Using a Cooled Radiofrequency System. *Pain Physician.* Sep 2019; 22(5): 489-494. PMID 31561648
20. McCormick ZL, Patel J, Conger A, et al. The Safety of Genicular Nerve Radiofrequency Ablation. *Pain Med.* Feb 23 2021; 22(2): 518-519. PMID 33517427
21. Radnovich R, Scott D, Patel AT, et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. *Osteoarthritis Cartilage.* Aug 2017; 25(8): 1247-1256. PMID 28336454

22. Gabriel RA, Ilfeld BM. Novel Methodologies in Regional Anesthesia for Knee Arthroplasty. *Anesthesiol Clin*. Sep 2018; 36(3): 387-401. PMID 30092936
23. Wu YT, Chang CY, Chou YC, et al. Ultrasound-Guided Pulsed Radiofrequency Stimulation of Posterior Tibial Nerve: A Potential Novel Intervention for Recalcitrant Plantar Fasciitis. *Arch Phys Med Rehabil*. May 2017; 98(5): 964-970. PMID 28209507
24. Landsman AS, Catanese DJ, Wiener SN, et al. A prospective, randomized, double-blinded study with crossover to determine the efficacy of radio-frequency nerve ablation for the treatment of heel pain. *J Am Podiatr Med Assoc*. Jan-Feb 2013; 103(1): 8-15. PMID 23328847
25. Cozzarelli J, Sollitto RJ, Thapar J, et al. A 12-year long-term retrospective analysis of the use of radiofrequency nerve ablation for the treatment of neurogenic heel pain. *Foot Ankle Spec*. Dec 2010; 3(6): 338-46. PMID 20817845
26. Cione JA, Cozzarelli J, Mullin CJ. A retrospective study of radiofrequency thermal lesioning for the treatment of neuritis of the medial calcaneal nerve and its terminal branches in chronic heel pain. *J Foot Ankle Surg*. Mar-Apr 2009; 48(2): 142-7. PMID 19232965
27. Grandhi RK, Kaye AD, Abd-Elsayed A. Systematic Review of Radiofrequency Ablation and Pulsed Radiofrequency for Management of Cervicogenic Headaches. *Curr Pain Headache Rep*. Feb 23 2018; 22(3): 18. PMID 29476360
28. Ducic I, Felder JM, Fantus SA. A systematic review of peripheral nerve interventional treatments for chronic headaches. *Ann Plast Surg*. Apr 2014; 72(4): 439-45. PMID 24374395
29. Kvarstein G, Hogstrom H, Allen SM, et al. Cryoneurolysis for cervicogenic headache - a double blinded randomized controlled study. *Scand J Pain*. Dec 18 2019; 20(1): 39-50. PMID 31675351
30. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Rheumatol*. Feb 2020; 72(2): 220-233. PMID 31908163
31. Schneider HP, Baca JM, Carpenter BB, et al. American College of Foot and Ankle Surgeons Clinical Consensus Statement: Diagnosis and Treatment of Adult Acquired Infracalcaneal Heel Pain. *J Foot Ankle Surg*. Mar 2018; 57(2): 370-381. PMID 29284574
32. Michael JW, Schluter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. *Dtsch Arztebl Int*. Mar 2010; 107(9): 152-62. PMID 20305774
33. Kapural L, Jolly S, Mantoan J, Badhey H, Ptacek T. Cooled radiofrequency neurotomy of the articular sensory branches of the obturator and femoral nerves – combined approach using fluoroscopy and ultrasound guidance: technical report, and observational study on safety and efficacy. *Pain Physician*. 2018;21(3):279-284. PMID: 29871372
34. Kapural L, Naber J, Neal K, Burchell M. Cooled radiofrequency ablation of the articular sensory branches of the obturator and femoral nerves using fluoroscopy and ultrasound guidance: a large retrospective study. *Pain Physician*. 2021;24(5):E611-E617. PMID: 34323448

35. Tran A, Reiter D, Wong PK, et al. Alternative treatment of hip pain from advanced hip osteoarthritis utilizing cooled radiofrequency ablation: single institution pilot study. *Skeletal Radiol.* 2022;51(5):1047-1054. doi:10.1007/s00256-021-03927-0
36. Blue Cross Blue Shield Association. Radiofrequency ablation of peripheral nerves to treat pain. *Medical Policy Reference Manual, MPRM 7.01.154.* Published September 2016. Last updated October 2021.
37. HAYES Medical Technology Brief. Peripheral nerve ablation for the treatment of osteoarthritic pain. Lansdale, PA: HAYES, Inc., published September 2017.
38. HAYES Evolving Evidence Review. The iovera° (Pacira BioSciences Inc.) System for Pain Associated with Total Knee Arthroplasty. Lansdale, PA: HAYES, Inc., published May 24, 2023.
39. HAYES Evolving Evidence Review. The iovera° (Pacira Biosciences Inc.) System for Knee Osteoarthritis. Lansdale, PA: HAYES, Inc., published Dec 20, 2022.
40. HAYES Evolving Evidence Review - Coolief Cooled RFA (Avanos Medical Inc.) for Hip Pain. Lansdale, PA: HAYES, Inc., published July 2021
41. HAYES Evolving Evidence Review - Coolief Cooled RF System (Avanos Medical Inc.) for Pain due to Degenerative Hip Disease, Lansdale, PA: HAYES, Inc., published Jan 26, 2023

The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through July 14, 2023, the date the research was completed.

Joint BCBSM/BCN Medical Policy History

Policy Effective Date	BCBSM Signature Date	BCN Signature Date	Comments
7/1/18	4/17/18	4/17/18	Joint policy established
7/1/19	4/16/19		Added Occipital Neuralgia and Cervicogenic Headache to MPS as E/I. Updated rationale, added reference 7 & 8.
7/1/20	4/14/20		Routine policy maintenance. Updated rationale section, added references. No change in policy status.
11/1/20	8/18/20		Added code 64625 as E/I. No changes in policy status.
11/1/21	8/17/21		Routine policy maintenance. No change in policy status.
11/1/22	8/16/22		Routine maintenance
11/1/23	8/15/23		Routine maintenance Added paragraph and Table 12 for Coolief Cooled RF System for Pain due to Degenerative Hip Disease under Rationale Vendor: N/A (ky)

Next Review Date: 3rd Qtr. 2024

Pre-Consolidation Medical Policy History

Original Policy Date	Comments
BCN:	Revised:
BCBSM:	Revised:

BLUE CARE NETWORK BENEFIT COVERAGE
POLICY: RADIOFREQUENCY ABLATION OF PERIPHERAL NERVES TO TREAT PAIN
INCLUDING COOLIEF COOLED RF

• Coverage Determination:

Commercial HMO (includes Self-Funded groups unless otherwise specified)	Not covered
BCNA (Medicare Advantage)	See government section.
BCN65 (Medicare Complementary)	Not covered

• Administrative Guidelines:

N/A